Our previous studies demonstrate that a non-cholinesterase inhibitor (AChEI) compound
catalpol, purified from a traditional Chinese medicinal herb Rehmannia glutinosa, could …

The purpose of this work is to study the effect of catalpol, an iridoid from Rehmannia
glutinosa on neurodegenerative changes induced by beta-amyloid peptide Aβ25–35 or …

Accumulating evidences demonstrated that epigenetic modification of the expression of
specific genes contributed to the pathogenesis of neurological disorders with dementia …

The pathogenesis of Alzheimer's disease (AD) has been linked to the deficiency of
neurotransmitter acetylcholine (ACh) in the brain, and the main treatment strategy for …

Deficiency of the cholinergic system is thought to play a vital role in cognitive impairment of
dementia. DL0410 was discovered as a dual inhibitor of acetylcholinesterase (AChE) and …

A previous study in humans demonstrated the sustained inhibitory effects of donepezil on
acetylcholinesterase (AChE) activity; however, the effective concentration of donepezil in …

Alzheimer's disease (AD) is progressive neurodegeneration known as the most common
cause of dementia, and it is the sixth leading cause of death in older people. Given the …

Galantamine, a drug for Alzheimer's disease, is a novel cholinergic agent with a dual mode
of action, which inhibits acetylcholinesterase and allosterically modulates nicotinic …

The use of acetylcholinesterase inhibitors to decrease the breakdown of the
neurotransmitter acetylcholine has been the main symptomatic therapy for mild to moderate …

We examined the potential protective effect of BDNF against β-amyloid-induced
neurotoxicity in vitro and in vivo in rats. In neuronal cultures, BDNF had specific and dose …